204 related articles for article (PubMed ID: 2364873)
1. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
2. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
Huang C; Bei L; Liu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
Robles-Diáz G; Aceves G; Galván E
Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
[TBL] [Abstract][Full Text] [Related]
4. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma].
Pei DP
Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
8. [Clinical evaluation of serum TAC-41 in various digestive cancers].
Sato S; Yamanaka T; Kimura K
Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
[TBL] [Abstract][Full Text] [Related]
9. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
Ishii M
Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
11. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
[TBL] [Abstract][Full Text] [Related]
12. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
14. [SC6 antigen for the diagnosis of pancreatic cancer before operation].
Guo XZ; Liu ZF; Ai R
Zhonghua Yi Xue Za Zhi; 1993 Jan; 73(1):26-8, 61-2. PubMed ID: 8389232
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
Chen YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
Safi F; Büchler M; Schenkluhn B; Beger HG
Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
18. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
[TBL] [Abstract][Full Text] [Related]
19. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
20. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
Schneider J; Schulze G
Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]